Join to access to all OVN content. Join for Free
The Augmented MSL
Artificial Intelligence in MSL AI tools in healthcare generative AI in medicine Pfizer AI integration MSL productivity AI

The Augmented MSL


Share This Article


Summary

This week's guest is Nandini Sabharwal, Director, Migraine and Women's Health, Field Medical Group at Pfizer and we discuss the role of artificial intelligence in every day MSL life.

Key Points

  • Embracing AI can significantly reduce preparation time for MSLs by providing quick, insightful answers and aiding in role-specific tasks such as healthcare provider meeting prep and advisory board planning.
  • Effective use of generative AI tools like ChatGPT or Microsoft Copilot requires learning how to craft detailed, specific prompts and understanding the limitations of these tools, including the necessity of refining the output manually.
  • Company buy-in and licensing are crucial for integrating AI tools into daily workflows, and while the initial learning curve can be steep, the productivity gains and potential for improved communication make it a worthwhile investment for MSLs.

Click for Source
Artificial Intelligence in MSL, AI tools in healthcare, generative AI in medicine, Pfizer AI integration, MSL productivity AI

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN